Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MTNB 
Matinas BioPharma Holdings Inc (MTNB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/27/2025: MTNB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -76.02% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.90M USD | Price to earnings Ratio - | 1Y Target Price 30 |
Price to earnings Ratio - | 1Y Target Price 30 | ||
Volume (30-day avg) 294958 | Beta 1.54 | 52 Weeks Range 0.48 - 11.25 | Updated Date 04/2/2025 |
52 Weeks Range 0.48 - 11.25 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.74 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-03-25 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -54.63% | Return on Equity (TTM) -108.57% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -4824419 | Price to Sales(TTM) 46.5 |
Enterprise Value -4824419 | Price to Sales(TTM) 46.5 | ||
Enterprise Value to Revenue 37.2 | Enterprise Value to EBITDA -1.79 | Shares Outstanding 5086980 | Shares Floating 4703884 |
Shares Outstanding 5086980 | Shares Floating 4703884 | ||
Percent Insiders 8.17 | Percent Institutions 7.06 |
Analyst Ratings
Rating 3 | Target Price 30 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Matinas BioPharma Holdings Inc
Company Overview
History and Background
Matinas BioPharma Holdings Inc. (MTNB) is a biopharmaceutical company focused on developing and commercializing therapeutics to treat serious unmet medical needs. Founded in 2011, it has evolved by focusing on lipid nanocrystal (LNC) delivery technology.
Core Business Areas
- LNC Platform Technology: Matinas BioPharma's primary focus is on its proprietary LNC platform, which is designed to improve the oral bioavailability and targeted delivery of drugs. This allows for improved safety and efficacy of various therapeutics.
Leadership and Structure
The company has a board of directors and an executive leadership team. Details about specific individuals and the organizational structure can be found on their investor relations website.
Top Products and Market Share
Key Offerings
- LYPDISOu2122: An investigational omega-3 fatty acid prescription drug product for the treatment of cardiovascular disease (CVD). Currently in clinical development. Market share is non-existent as the product is not yet approved. Competitors include Amarin (AMRN) with Vascepa, and other omega-3 supplements.
- MAT2203: An investigational oral formulation of amphotericin B, a potent antifungal, using the LNC platform. Aimed at treating invasive fungal infections. Market share is non-existent as the product is not yet approved. Potential competitors include Gilead Sciences (GILD) with AmBisome and other antifungal treatments.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with a growing demand for novel therapeutics and drug delivery systems. The focus is shifting toward personalized medicine and innovative technologies.
Positioning
Matinas BioPharma is positioned as a company developing innovative drug delivery technologies to enhance the efficacy and safety of existing and new drug candidates. Its LNC platform provides a potential competitive advantage.
Total Addressable Market (TAM)
The TAM for cardiovascular disease and antifungal treatments is multi-billion dollar. Matinas BioPharma is aiming to capture a portion of this market by improving the efficacy and safety profiles of existing drugs using its LNC platform.
Upturn SWOT Analysis
Strengths
- Proprietary LNC platform technology
- Potential for improved oral bioavailability of drugs
- Focus on unmet medical needs
- Experienced management team
Weaknesses
- Dependence on clinical trial success
- Limited product portfolio
- Lack of currently marketed products
- Reliance on funding for research and development
Opportunities
- Partnerships with pharmaceutical companies
- Expansion of LNC platform to new therapeutic areas
- Regulatory approval of LYPDISO and MAT2203
- Addressing unmet needs in the treatment of fungal infections and cardiovascular diseases
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- AMRN
- GILD
Competitive Landscape
Matinas BioPharma's competitors are generally larger and have greater resources. Matinas BioPharma's LNC platform offers a differentiated approach, but its success depends on proving its clinical benefits.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily based on the advancement of its LNC platform and clinical trial progress.
Future Projections: Future growth depends on the successful development and commercialization of LYPDISO and MAT2203.
Recent Initiatives: Recent initiatives include advancing clinical trials for LYPDISO and MAT2203, as well as exploring new applications for the LNC platform.
Summary
Matinas BioPharma is a development-stage biopharmaceutical company with a promising LNC delivery platform. Its future relies heavily on the success of its ongoing clinical trials, particularly for LYPDISO and MAT2203. The lack of revenue and dependence on funding pose risks, while successful drug development could significantly increase shareholder value. Competitors with larger resources present a challenge but Matinas' differentiation is strong if the trials pan out.
Similar Companies
AMRN
Amarin Corporation PLC
AMRN
Amarin Corporation PLC
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Third Party Financial Data Providers
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Market share estimates are approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Matinas BioPharma Holdings Inc
Exchange NYSE MKT | Headquaters Bedminster, NJ, United States | ||
IPO Launch date 2014-08-18 | Co-Founder, CEO, President & Director Mr. Jerome D. Jabbour J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 32 | Website https://www.matinasbiopharma.com |
Full time employees 32 | Website https://www.matinasbiopharma.com | ||
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It also offers MAT2501, an orally administered formulation of amikacin to treat chronic and acute bacterial infections, as well as non-tuberculosis mycobacterium. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases for the development of oral formulations of Gilead's remdesivir; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.